Cheremina Olga, Brune Kay, Hinz Burkhard
Department of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander University Erlangen-Nürnberg, Fahrstrasse 17, D-91054 Erlangen, Germany.
Biomed Chromatogr. 2006 Oct;20(10):1033-7. doi: 10.1002/bmc.633.
Lumiracoxib {2-[(2-fluoro-6-chlorophenyl)amino]-5-methyl-benzeneacetic acid} is a highly selective and potent cyclooxygenase-2 (COX-2) inhibitor, which is chemically distinct from other coxibs in that it contains a carboxylic group and is weakly acidic. In the present study, a liquid-liquid extraction-based reversed-phase HPLC method with UV detection was validated and applied for the analysis of lumiracoxib in human plasma. The analyte was separated on a reversed-phase column with acetonitrile and 0.05% trichloracetic acid in water (35:65, v/v) as mobile phase at a flow rate of 1 mL/min, and UV detection at 270 nm. The retention times for lumiracoxib and niflumic acid (internal standard) were 16.9 and 10.4 min, respectively. The validated quantitation range for lumiracoxib was 10-10,000 ng/mL. The developed procedure was applied to assess the pharmacokinetics of lumiracoxib following administration of a single oral 200 mg dose to a healthy male volunteer.
鲁米昔布{2-[(2-氟-6-氯苯基)氨基]-5-甲基苯乙酸}是一种高选择性且强效的环氧化酶-2（COX-2）抑制剂，其化学结构与其他昔布类药物不同，它含有一个羧基且呈弱酸性。在本研究中，一种基于液液萃取的反相高效液相色谱法结合紫外检测被验证并应用于分析人血浆中的鲁米昔布。分析物在反相柱上分离，流动相为乙腈和0.05%三氯乙酸水溶液（35:65，v/v），流速为1 mL/min，紫外检测波长为270 nm。鲁米昔布和尼氟灭酸（内标）的保留时间分别为16.9分钟和10.4分钟。鲁米昔布的验证定量范围为10 - 10,000 ng/mL。所建立的方法应用于评估一名健康男性志愿者单次口服200 mg剂量后鲁米昔布的药代动力学。
Zotero 插件